Terms: = Leukemia AND SMAD3, JV15-2, 4088, ENSG00000166949, P84022, Smad3, MADH3, HsT17436, Smad 3, DKFZp686J10186, HSPC193, DKFZP586N0721, MGC60396 AND Diagnosis
4 results:
1. Biological activity of human IgE monoclonal antibodies targeting Der p 2, Fel d 1, Ara h 2 in basophil mediator release assays.
Pena-Castellanos G; Smith BRE; Pomés A; Smith SA; Stigler MA; Widauer HL; Versteeg SA; van Ree R; Chapman MD; Aglas L
Front Immunol; 2023; 14():1155613. PubMed ID: 37228609
[TBL] [Abstract] [Full Text] [Related]
2. The miR-200c/141-ZEB2-TGFβ axis is aberrant in human T-cell prolymphocytic leukemia.
Erkeland SJ; Stavast CJ; Schilperoord-Vermeulen J; Dal Collo G; Van de Werken HJG; Leon LG; Van Hoven-Beijen A; Van Zuijen I; Mueller YM; Bindels EM; De Ridder D; Kappers-Klunne MC; Van Lom K; Van der Velden VHJ; Langerak AW
Haematologica; 2022 Jan; 107(1):143-153. PubMed ID: 33596640
[TBL] [Abstract] [Full Text] [Related]
3. High expression levels of smad3 and smad7 at diagnosis predict poor prognosis in acute myeloid leukemia patients undergoing chemotherapy.
Zhang J; Zhang L; Cui H; Zhang X; Zhang G; Yang X; Yang S; Zhang Z; Wang J; Hu K; Shi J; Ke X; Fu L
Cancer Gene Ther; 2019 May; 26(5-6):119-127. PubMed ID: 30177817
[TBL] [Abstract] [Full Text] [Related]
4. Loss of smad3 in acute T-cell lymphoblastic leukemia.
Wolfraim LA; Fernandez TM; Mamura M; Fuller WL; Kumar R; Cole DE; Byfield S; Felici A; Flanders KC; Walz TM; Roberts AB; Aplan PD; Balis FM; Letterio JJ
N Engl J Med; 2004 Aug; 351(6):552-9. PubMed ID: 15295048
[TBL] [Abstract] [Full Text] [Related]
